A Phase 4 interventional study of EV71 vaccine and influenza vaccine and EV71 vaccine in Enterovirus Infections and Influenza, sponsored by China National Biotec Group Company Limited. Completed at 1 site in China. Open to participants aged 6 Months to 11 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-12.
Sponsored by China National Biotec Group Company Limited (part of Sinopharm) · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Subjects will be recruited and divided into 3 groups:
All blood samples will be collected before and one month after vaccinatioin. The immunogenicity and safety of both experimental and control groups will be compared and the data be analyzed.
To further evaluate the feasibility of simultaneously administration of EV71 vaccine and flu vaccine, we design this clinical trial to test its immunogenicity and safety. 1134 subjects aged from 6 to 11 months old are divided into one experimental group and two control groups (control group A and B).
378 subjects from the experimental group will be simultaneously administrated with one dose of EV71 vaccine (0.5 ml) and one dose of influenza vaccine (0.25 ml). One month later, they are going to receive a second dose of EV71 vaccine and influenza vaccine, simultaneously. Blood samples are collected before the first vaccination, and one month following the second vaccination.
378 subjects from the control group A will be only administrated with two doses of EV71 vaccine (0.5 ml) (1 month apart). Blood samples are collected before the first vaccination, and one month following the second vaccination.
378 subjects from the control group B will be only administrated with two doses of influenza vaccine (0.25 ml) (1 month apart). Blood samples are collected before the first vaccination, and one month following the second vaccination.
To evaluate the immunogenicity, we will detect and compare the neutralization antibody levels, the seroprotection rates, and antibody geometric mean concentrations. The safety of all groups will be monitored as well.
48 studies on the registry are indexed under Enterovirus Infections; 3 are open to participants now.
This study's enrollment of 1,134 is above the median of 132 across 31 interventional studies indexed under Enterovirus Infections.
Browse Enterovirus Infections studies →China National Biotec Group Company Limited is the lead sponsor of 37 studies on the registry; 2 are open to participants now.
First submitted after China National Biotec Group Company Limited became part of Sinopharm.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
378 subjects from the experimental group will be simultaneously administrated with one dose of EV71 vaccine (0.5 ml) and one dose of influenza vaccine (0.25 ml). One month later, they are going to receive a second dose of EV71 vaccine and influenza vaccine, simultaneously.
Biological: EV71 vaccine and influenza vaccine
378 subjects from the control group A will be only administrated with two doses of EV71 vaccine (0.5 ml) (1 month apart).
Biological: EV71 vaccine
378 subjects from the control group B will be only administrated with two doses of influenza vaccine (0.25 ml) (1 month apart).
Biological: influenza vaccine
Drug page: EV71
simultaneously administrated with EV71 vaccine and influenza vaccine
administrated with EV71 vaccine only
administrated with influenza vaccine only
Seroconversion rate I
the rate of positive seroconversion against EV71
Time frame: Baseline (before vaccination) and 1 month after the last dose
Seroconversion rate II
the rate of positive seroconversion against Influenza A (H3N2, H1N1) and B Type viruses
Time frame: Baseline (before vaccination ) and 1 month after the last dose
Geometric mean titer (GMT) I
Measure neutralizing antibody titers against EV71
Time frame: Baseline (before vaccination) and 1 month after the last dose
Geometric mean titer (GMT) II
Measure neutralizing antibody titers against Influenza A (H3N2, H1N1) and B Type viruses
Time frame: Baseline (before vaccination) and 1 month after the last dose
adverse events following vaccination
analyse the numbers and rates of participants who experience adverse events following immunization
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2019 to primary completion in Jan 2020, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EV71
China National Biotec Group Company Limited →